PTIP associates with Artemis to dictate DNA repair pathway choice.

Abstract

PARP inhibitors (PARPis) are being used in patients with BRCA1/2 mutations. However, doubly deficient BRCA1(-/-)53BP1(-/-) cells or tumors become resistant to PARPis. Since 53BP1 or its known downstream effectors, PTIP and RIF1 (RAP1-interacting factor 1 homolog), lack enzymatic activities directly implicated in DNA repair, we decided to further explore the… (More)
DOI: 10.1101/gad.252478.114

Topics

  • Presentations referencing similar topics